Joint Pediatric Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee Meeting (May 2018)

Pretty soon, I’m getting the opportunity to speak (again) with members of the U.S. Food and Drug Administration to express the urge for why there need to be pharmaceutical treatment options on the market for those with achondroplasia. The last time I spoke with the FDA was in 2018. Since I’m getting the chance to do it again soon, I thought I would share my words from then.